Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.

Journal of thrombosis and haemostasis : JTH - 1 Jun 2014

Quade-Lyssy P, Milanov P, Abriss D, Ungerer C, Königs C, Seifried E, Schüttrumpf J

Abstract excerpt

BACKGROUND: Oral gene delivery of non-viral vectors is an attractive strategy to achieve transgene expression. Although expected efficacy from non-viral delivery systems is relatively low, repeated vector administration is possible and may help to obtain durable transgene expression in a therapeutic range. OBJECTIVES: To test the principle feasibility of using factor (F) IX variants with improved function...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Chitosan
Share to Factor IX

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feasibility Studies

Share to Hemophilia B

Share to Hemostasis

Share to Intestine, Small

Share to Nanoparticles

Source

Identifiers

PMID: 24679056
DOI: 10.1111/jth.12572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.PMID 24679056Read ↗

Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomesSemantic proximity Read ↗

Hemophilia Gene Therapy: Ready for Prime Time?Semantic proximity Read ↗

Hemophilia B: Analysis of Mutations in the F9 Gene and Perspectives for the Development of Gene Therapy (A Review)Semantic proximity Read ↗

Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.Semantic proximity Read ↗

Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX.Semantic proximity Read ↗

Gene therapy for hemophiliaSemantic proximity Read ↗

CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B MiceSemantic proximity Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.Semantic proximity Read ↗

Coagulation Factor IX for Hemophilia B TherapySemantic proximity Read ↗

Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.Semantic proximity Read ↗

Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.